Navigation Links
Boehringer Ingelheim's interferon-free hepatitis C treatment portfolio strengthened by promising interim Phase 2a data
Date:11/2/2013

the CT and TT IL28B genotypes led to a reduced likelihood of achieving viral cure. In addition, more than half the patients in the study (20/36) have pre-existing HCV mutations. These include the Q80K variant in 12 of these patients, all of which had virologic responses to the faldaprevir-based triple direct-acting antiviral (DAA) regimen. Also in this trial, 19% of patients are African American.

"These results add to the growing body of data for HCV regimens containing our investigational compound, faldaprevir," said Peter Piliero, M.D., vice president, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "We are looking forward to the final results of this trial, as well as our other studies evaluating all-oral regimens, as researchers strive to make an interferon-free future a reality for a broad range of HCV patients."

This study contains three arms:

  • The first arm enrolled 12 patients and is evaluating faldaprevir 120mg once-daily (QD), PPI-668 200mg once-daily (QD) and deleobuvir 600mg twice-daily (BID) with ribavirin
  • The second arm enrolled 12 patients and is evaluating faldaprevir 120mg QD, PPI-668 200mg QD and deleobuvir 400mg BID with ribavirin
  • The third arm enrolled 12 patients and is evaluating faldaprevir 120mg QD, PPI-668 200mg QD and deleobuvir 600mg BID without ribavirin

All patients in the study have received at least 4 weeks of treatment and 97% (35/36) achieved LLOQ. To date, one patient who had pre-existing NS5A and NS5B mutations failed treatment. This patient had a partial response to treatment but developed viral breakthrough and was discontinued.

To date, there has been one treatment discontinuation due to adverse events. The patient self-discontinued at week 9 on treatment due to gastrointestinal side effects. This patient had undetectable levels of HCV RNA by day 10 of trea
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... SHENZHEN , Chine, 3 juillet 2015 ... séquençage à haut débit de l,ADN situé à ... la certification de  l,American College of Pathologists  (Collège ... BGI à Hong Kong ... nouvelle génération à recevoir la certification du CAP ...
(Date:7/2/2015)... and VANCOUVER , July 2, 2015 ... EPI) announced today that its common shares have been approved ... under the symbol "EPIX". ESSA will begin trading ... its listing on the TSX Venture Exchange under the symbol ... the common shares on the NASDAQ, each of the Company,s ...
(Date:7/2/2015)... July 2, 2015  New product launches are critical ... role in educating thought leaders about new products, Medical ... influence how well a new therapy performs at launch. ... research and consulting leader Best Practices, LLC, critical aspects ... focus on are early stage thought leader (TL) interaction, ...
Breaking Medicine Technology:BGI obtient la certification du Collège des pathologistes américains (CAP) 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 4Medical Affairs Role in Thought Leader Education is Key Success Factor for New Product Launches in the Pharmaceutical Industry 2
... DALLAS, April 4, 2008 Data from five ... presented at the National Kidney,Foundation (NKF) 2008 Spring ... utilization studies involve PROCRIT(R) (Epoetin alfa)., The ... and,costs of PROCRIT (EPO) and darbepoetin alfa (DARB), ...
... Previously-Stated Guidance Remains Unchanged, PRINCETON, N.J., ... MEDX ) today issued the following statement ... that it was discontinuing its Phase 3 ... anti-CTLA-4,antibody (tremelimumab) compared to chemotherapy in patients ...
Cached Medicine Technology:Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 2Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 3Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 4Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 5Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 6Medarex Announces Ipilimumab Program Continues to Move Forward 2Medarex Announces Ipilimumab Program Continues to Move Forward 3Medarex Announces Ipilimumab Program Continues to Move Forward 4Medarex Announces Ipilimumab Program Continues to Move Forward 5
(Date:7/3/2015)... ... July 03, 2015 , ... The Erie County Bar Association ... 1:00pm. The Association welcomed speaker C. Daniel McGillicuddy Esq. of William Mattar Law ... of investigating these types of cases. , Each year, New York State residents ...
(Date:7/3/2015)... ... July 03, 2015 , ... " Selfie on a ... features the latest and coolest technology products available to consumers. Amanda Forstrom, a technology ... these selfie sticks are great for documenting memories. , Almost every smartphone has an ...
(Date:7/2/2015)... ... ... sweetFrog Enterprises, LLC. is pleased to announce the opening of its newest location in Dallas, ... The premium frozen yogurt chain was listed as #22 on the Inc. 500 list of ... at Bachman Lake, is located at:, 3701 W. Northwest Highway, STE 430, Dallas, TX 75220 ...
(Date:7/2/2015)... RI (PRWEB) , ... July 02, 2015 , ... Many ... safety in mind. That’s why Amica Insurance is sharing some tips to ... Commission (CPSC), approximately 230 people go to the emergency room daily with fireworks-related injuries ...
(Date:7/2/2015)... ... July 02, 2015 , ... Get ready to hit the ... Since the socks were first introduced, they have rapidly been gaining attention among ... four new, fun shades including: blue, lime, pink and red. , Utilizing ...
Breaking Medicine News(10 mins):Health News:Attorney from William Mattar Leads Discussion on Bicycle Accidents 2Health News:Learn How to Take Selfies like Kendall Jenner 2Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:6 Fireworks Safety Tips from Amica Insurance 2Health News:SIGVARIS is Sporting Four Brand New Colors in the Popular PERFORMANCE SOCK Product Line 2
... N.J., Nov. 2 comScore, Inc. (Nasdaq: ... world, and ImpactRx, a pharmaceutical insights company, today announced ... the only digital measurement solution that connects physicians, online ... This solution is carefully designed to comply with health ...
... to develop the disorder, study finds, , MONDAY, Nov. 2 ... by a strong urge to move the legs, is much ... U.S. study has found. , Researchers interviewed 190 people being ... those who were black, compared with 36 percent of those ...
... developing the brain disease, study finds , MONDAY, Nov. ... Alzheimer,s disease are at increased risk for high blood ... -- all of which may be associated with later ... a study by researchers in the Netherlands who compared ...
... PNAS provides a comprehensive comparative functional anatomy study in ... networks preserved across evolution. An international collaboration co-led ... York City examined patterns of connectivity to show that ... is actually divided into four distinct functional regions. ...
... walkability (degree of ease for walking) with local levels ... be good for walking, but have poor air quality. ... faculty member Julian Marshall and University of British Columbia ... highlight the need for urban design to consider both ...
... Richard L. ... ... Chief Executive Officer of Jackson Healthcare ®, Richard L. Jackson, will present at the ... Jackson will be part of a discussion panel addressing the tort reform debate and control ...
Cached Medicine News:Health News:comScore Announces Availability of comScore/ImpactRx Physician Behavioral Measurement(TM) Solution 2Health News:comScore Announces Availability of comScore/ImpactRx Physician Behavioral Measurement(TM) Solution 3Health News:Restless Legs May Vary by Race and Gender 2Health News:High Blood Pressure Likely in Alzheimer's Offspring 2Health News:Researchers discover links between city walkability and air pollution exposure 2Health News:Researchers discover links between city walkability and air pollution exposure 3Health News:CEO of Jackson Healthcare to Speak at Physicians' Council for Responsible Reform Upcoming Strategy Meeting 2Health News:CEO of Jackson Healthcare to Speak at Physicians' Council for Responsible Reform Upcoming Strategy Meeting 3
Used for temporary control of male urinary incontinence due to surgery or neurogenic disorder. Supplied non-sterile. Reusable. Intended for single patient use only....
... ideally suited for high volume stone centers. This ... and an advanced urological table. With the Dornier ... provides successful treatments for a full range of ... URS and PCN procedures are easy. One of ...
Used for male external catheterization due to urinary incontinence. The inflatable retention ring secures the catheter and can be easily deflated for removal. Supplied non-sterile. Reusable. Intended...
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
Medicine Products: